Balyasny Asset Management
ORKA

Balyasny Asset Management’s Oruka Therapeutics ORKA Stock Holding History

Balyasny Asset Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-536
Closed -$16.2K – 3672
2025
Q4 		$16.2K Buy
+536
New +$14.9K ﹤0.01% 3019

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Balyasny Asset Management's ORKA Position: Q1 2026 in Review

Balyasny Asset Management sold out of Oruka Therapeutics (ORKA) in Q1 2026, closing a stake of 536 shares — an estimated $16.2K sold.

Balyasny Asset Management first reported a position in ORKA in Q4 2025 and held it in 1 quarter. The position peaked at $16.2K in Q4 2025. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Balyasny Asset Management reported no remaining Oruka Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 536 Oruka Therapeutics shares in Q1 2026, an estimated $16.2K.
  • Balyasny Asset Management first reported a position in Oruka Therapeutics in Q4 2025 and held it in 1 quarter.
  • Balyasny Asset Management's Oruka Therapeutics position peaked at $16.2K in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.